BIOTECH MARKET RESEARCH $SLN | Ep. 1044

SIlence Therapeutics

Silence Therapeutics ($SLN) is a catalyst-driven setup centered on the expected Q3 2026 topline readout from SANRECO Phase 2 in polycythemia vera. This is not primarily a platform catalyst. It is a very specific randomized clinical test: can divesiran, a fixed-dose TMPRSS6-targeting siRNA administered every six or twelve weeks, keep hematocrit below 45% while eliminating the need for phlebotomy in patients who currently require repeated blood removal to control their disease. The Phase 2 study is fully enrolled with 48 phlebotomy-dependent patients and uses a 36-week placebo-controlled, double-blind period. The primary endpoint is the proportion of patients who maintain hematocrit below 45% without phlebotomy between weeks 18 and 36.

The bull case is that the Phase 1 signal was unusually consistent across efficacy, mechanism and durability. The 21 enrolled patients had undergone 79 phlebotomies before dosing, yet no well-controlled patient required a phlebotomy during the six-month treatment period. Divesiran also reduced hematocrit and hemoglobin across patients regardless of baseline levels, produced sustained hepcidin increases and showed a median time to first phlebotomy of 287 days among 14 patients with follow-up data, with several patients remaining phlebotomy-free nearly one year after their last dose. Bulls will argue that this is exactly the pattern expected from a durable RNAi therapy: rapid biological activity, prolonged control between doses and a clinically tangible reduction in treatment burden.

The bear case is that all of the impressive efficacy evidence still comes from a 21-patient, open-label, dose-finding study with no placebo comparator. Stable background cytoreductive therapy was permitted, baseline hematocrit was not standardized and the study was designed primarily around safety, tolerability and changes in phlebotomy frequency. The randomized Phase 2 therefore has to show that the apparent elimination of phlebotomies was caused by divesiran rather than patient selection, background treatment, clinical discretion or the natural variability of disease management. Bulls will call the phlebotomy, hematocrit, hepcidin and durability findings a coherent disease-control package. Bears will call it a striking but very small uncontrolled dataset waiting for the first rigorous confirmation.

Safety has been reassuring so far, but the key issue is not simply whether divesiran is tolerated. Phase 1 showed no dose-limiting toxicities, no treatment-related serious adverse events and no treatment-emergent adverse events leading to discontinuation. The more important question is whether a long-acting therapy that raises hepcidin and restricts iron availability can maintain hematocrit control without overshooting into clinically meaningful anemia, excessive hemoglobin reduction or new iron-related symptoms. The Phase 2 readout also needs to clarify whether every-twelve-week dosing performs comparably to every-six-week dosing, because a clean quarterly regimen would materially strengthen the commercial profile.

So the catalyst is not just whether SANRECO Phase 2 technically meets its primary endpoint. The catalyst is whether divesiran produces a large, durable and clinically clean separation from placebo, with few rescue phlebotomies, consistent hematocrit control and enough safety comfort to support pivotal development as a first-line option for phlebotomy-dependent polycythemia vera. A strong result across both dosing schedules would allow investors to underwrite Silence as a late-stage rare-disease company with a potentially differentiated chronic therapy. A narrow statistical win with modest treatment separation, inconsistent Q12W performance or evidence of excessive hematologic suppression would leave a real development asset, but with a weaker commercial argument and much less support for the first-in-class premium embedded in the story.

Every Monday we are out with public biotech research, profiling biotech companies with near term catalysts. This will focus primarily on the major market moving biotech events such as data readouts from the major scientific conferences as well as potential regulatory approvals.

We will not offer specific trading advice (and we do not hold any publicly traded biotech equity), but rather flag emerging events that will likely materially drive stock prices (sometimes +/-100% in either direction).

Be sure to SUBSCRIBE to not miss.

HOW TO PLAY BIOTECH APPROVAL/DATA READOUTS ANNOUNCEMENTS

While biotech equities will move on news of announcement, often if there is high conviction in a positive read, a large run up ahead of the news will occur and the actual event turns into a sell the news event. Sometimes, investors wait for the actual event to make a long/short decision. And obviously if the news is disappointing (more often than not) the stock will tank.

This is not financial advice so you will have to make your own call on how to best play these events. Our aim is simply to flag catalysts with high projected volatility.

🚨 ALERT: SANRECO Phase 2 – Divesiran in Polycythemia Vera

📅 TIMING: Q3 2026

📈 IMPLIED MOVE: ~±130%

BACKGROUND: